Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome

Hasina Maredia; Antonio Cozzio; Reinhard Dummer; Egle Ramelyte; Ellen J. Kim; Sima Rozati

doi:10.1016/j.jdcr.2021.07.007

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome

Hasina Maredia, Antonio Cozzio, Reinhard Dummer, Egle Ramelyte, Ellen J. Kim, Sima Rozati

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	92-96
Number of pages	5
Journal	JAAD Case Reports
Volume	15
DOIs	https://doi.org/10.1016/j.jdcr.2021.07.007
State	Published - Sep 2021

Keywords

CTCL classifications
Sézary syndrome
T cell
clinical cases
leukemic progression
lymphoma
medical dermatology
mycosis fungoides

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jdcr.2021.07.007

Cite this

@article{603701d63d064b518dde39310071d094,

title = "Acute progression of the leukemic phase in mycosis fungoides and S{\'e}zary syndrome",

keywords = "CTCL classifications, S{\'e}zary syndrome, T cell, clinical cases, leukemic progression, lymphoma, medical dermatology, mycosis fungoides",

author = "Hasina Maredia and Antonio Cozzio and Reinhard Dummer and Egle Ramelyte and Kim, {Ellen J.} and Sima Rozati",

note = "Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma ; personal fees from Helsinn and Almirall; and grants from MedImmune , Kyowa Kirin , and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma; personal fees from Helsinn and Almirall; and grants from MedImmune, Kyowa Kirin, and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding sources: None.",

year = "2021",

month = sep,

doi = "10.1016/j.jdcr.2021.07.007",

language = "English (US)",

volume = "15",

pages = "92--96",

journal = "JAAD Case Reports",

issn = "2352-5126",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome

AU - Maredia, Hasina

AU - Cozzio, Antonio

AU - Dummer, Reinhard

AU - Ramelyte, Egle

AU - Kim, Ellen J.

AU - Rozati, Sima

N1 - Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma ; personal fees from Helsinn and Almirall; and grants from MedImmune , Kyowa Kirin , and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding Information: Dr Dummer reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp and Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Dr Ramelyte reports intermittent, project-focused consulting and/or advisory relationships with Amgen, Novartis, Sanofi, Pierre Fabre, and Sun Pharma outside the submitted work. Dr Kim reports grants and personal fees from Actelion and Galderma; personal fees from Helsinn and Almirall; and grants from MedImmune, Kyowa Kirin, and Soligenix outside the submitted work. Drs Maredia, Cozzio, and Rozati have no conflicts of interest to declare. Funding sources: None.

PY - 2021/9

Y1 - 2021/9

KW - CTCL classifications

KW - Sézary syndrome

KW - T cell

KW - clinical cases

KW - leukemic progression

KW - lymphoma

KW - medical dermatology

KW - mycosis fungoides

UR - http://www.scopus.com/inward/record.url?scp=85112753016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112753016&partnerID=8YFLogxK

U2 - 10.1016/j.jdcr.2021.07.007

DO - 10.1016/j.jdcr.2021.07.007

M3 - Article

C2 - 34458536

AN - SCOPUS:85112753016

SN - 2352-5126

VL - 15

SP - 92

EP - 96

JO - JAAD Case Reports

JF - JAAD Case Reports

ER -

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this